Structural modulation of p53TAD1-TAZ2 complex upon mutations and post-translational modification

References

• Appella, E., & Anderson, C. W. (2001). Post-translational modifications and activation of p53 by genotoxic stresses. European Journal of Biochemistry, 268(10), 2764–2772. https://doi.org/10.1046/j.1432-1327.2001.02225.x
   PubMedGoogle Scholar
• Bode, A. M., & Dong, Z. (2004). Post-translational modification of p53 in tumorigenesis. Nature Reviews. Cancer, 4(10), 793–805. https://doi.org/10.1038/nrc1455
   PubMed Web of Science ®Google Scholar
• Brooks, B. R., Brooks, C. L., 3rd, Mackerell, A. D., Jr., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., Caflisch, A., Caves, L., Cui, Q., Dinner, A. R., Feig, M., Fischer, S., Gao, J., Hodoscek, M., Im, W., … Karplus, M. (2009). CHARMM: The biomolecular simulation program. Journal of Computational Chemistry, 30(10), 1545–1614. https://doi.org/10.1002/jcc.21287
   PubMed Web of Science ®Google Scholar
• Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983). CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. Journal of Computational Chemistry, 4(2), 187–217. https://doi.org/10.1002/jcc.540040211
   Web of Science ®Google Scholar
• Brown, C. J., Srinivasan, D., Jun, L. H., Coomber, D., Verma, C. S., & Lane, D. P. (2008). The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle (Georgetown, Tex.), 7(5), 608–610. https://doi.org/10.4161/cc.7.5.5488
   PubMed Web of Science ®Google Scholar
• Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science (New York, N.Y.), 265(5170), 346–355. https://doi.org/10.1126/science.8023157
   PubMed Web of Science ®Google Scholar
• Cho, H. S., Liu, C. W., Damberger, F. F., Pelton, J. G., Nelson, H. C., & Wemmer, D. E. (1996). Yeast heat shock transcription factor N-terminal activation domains are unstructured as probed by heteronuclear NMR spectroscopy. Protein Science : A Publication of the Protein Society, 5(2), 262–269. https://doi.org/10.1002/pro.5560050210
   PubMed Web of Science ®Google Scholar
• Clore, G. M., Ernst, J., Clubb, R., Omichinski, J. G., Kennedy, W. M., Sakaguchi, K., Appella, E., & Gronenborn, A. M. (1995). Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Structural Biology, 2(4), 321–333. https://doi.org/10.1038/nsb0495-321
   PubMedGoogle Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle Mesh Ewald: An N.log(N) method for Ewald sums in large systems. Journal of Chemical Physics., 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Web of Science ®Google Scholar
• David, C. C., & Jacobs, D. J. (2014). Principal component analysis: A method for determining the essential dynamics of proteins. Methods in Molecular Biology (Clifton, N.J.), 1084, 193–226.
   PubMedGoogle Scholar
• Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995). A smooth particle mesh Ewald potential. Journal of Chemical Physics, 103(19), 8577–8592. https://doi.org/10.1063/1.470117
   Web of Science ®Google Scholar
• Feng, H., Jenkins, L. M., Durell, S. R., Hayashi, R., Mazur, S. J., Cherry, S., Tropea, J. E., Miller, M., Wlodawer, A., Appella, E., & Bai, Y. (2009). Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure (London, England : 1993), 17(2), 202–210. https://doi.org/10.1016/j.str.2008.12.009
   PubMed Web of Science ®Google Scholar
• Fields, S., & Jang, S. K. (1990). Presence of a potent transcription activating sequence in the p53 protein. Science (New York, N.Y.), 249(4972), 1046–1049. https://doi.org/10.1126/science.2144363
   PubMed Web of Science ®Google Scholar
• Ganguly, D., & Chen, J. (2009). Atomistic details of the disordered states of KID and pKID. Implications in coupled binding and folding. Journal of the American Chemical Society, 131(14), 5214–5223.
   PubMed Web of Science ®Google Scholar
• Ganguly, D., & Chen, J. (2015). Modulation of the disordered conformational ensembles of the p53 transactivation domain by cancer-associated mutations. PLoS Computational Biology, 11(4), e1004247. https://doi.org/10.1371/journal.pcbi.1004247
   PubMed Web of Science ®Google Scholar
• Green, D. R., & Kroemer, G. (2009). Cytoplasmic functions of the tumour suppressor p53. Nature, 458(7242), 1127–1130. https://doi.org/10.1038/nature07986
   PubMed Web of Science ®Google Scholar
• Hahn, S. (1993). Structure and function of acidic transcription activators. Cell, 72(4), 481–483. https://doi.org/10.1016/0092-8674(93)90064-W
   PubMed Web of Science ®Google Scholar
• Huang, J., & MacKerell, A. D. Jr. (2013). CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data. Journal of Computational Chemistry, 34(25), 2135–2145. https://doi.org/10.1002/jcc.23354
   PubMed Web of Science ®Google Scholar
• Huang, J., Rauscher, S., Nawrocki, G., Ran, T., Feig, M., de Groot, B. L., Grubmüller, H., & MacKerell, A. D. Jr. (2017). CHARMM36m: An improved force field for folded and intrinsically disordered proteins. Nature Methods, 14(1), 71–73. https://doi.org/10.1038/nmeth.4067
   PubMed Web of Science ®Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38. 27, –38.
   PubMedGoogle Scholar
• Hunter, J. D. (2007). Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering, 9(3), 90–95. https://doi.org/10.1109/MCSE.2007.55
   Web of Science ®Google Scholar
• Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986). Localization of gene for human p53 tumour antigen to band 17p13. Nature, 320(6057), 84–85. https://doi.org/10.1038/320084a0
   PubMed Web of Science ®Google Scholar
• Ithuralde, R. E., & Turjanski, A. G. (2016). Phosphorylation Regulates the Bound Structure of an Intrinsically Disordered Protein: The p53-TAZ2 Case. PLoS One, 11(1), e0144284. https://doi.org/10.1371/journal.pone.0144284
   PubMed Web of Science ®Google Scholar
• Jo, S., Cheng, X., Islam, S. M., Huang, L., Rui, H., Zhu, A., Lee, H. S., Qi, Y., Han, W., Vanommeslaeghe, K., & MacKerell, A. D., Jr. (2014). CHARMM-GUI PDB manipulator for advanced modeling and simulations of proteins containing nonstandard residues. Advances in Protein Chemistry and Structural Biology, 96, 235–265.
   PubMed Web of Science ®Google Scholar
• Joerger, A. C., & Fersht, A. R. (2007). Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene, 26(15), 2226–2242. https://doi.org/10.1038/sj.onc.1210291
   PubMed Web of Science ®Google Scholar
• Jo, S., Kim, T., Iyer, V. G., & Im, W. (2008). CHARMM-GUI: A web-based graphical user interface for CHARMM. Journal of Computational Chemistry, 29(11), 1859–1865.
   PubMed Web of Science ®Google Scholar
• Jolliffe, I. T., & Cadima, J. (2016). Principal component analysis: A review and recent developments. Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences, 374(2065), 20150202.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science (New York, N.Y.), 252(5013), 1708–1711. https://doi.org/10.1126/science.2047879
   PubMed Web of Science ®Google Scholar
• Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (New York, N.Y.), 274(5289), 948–953. https://doi.org/10.1126/science.274.5289.948
   PubMed Web of Science ®Google Scholar
• Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., & Arrowsmith, C. H. (1994). Solution structure of the tetrameric minimum transforming domain of p53. Nature Structural Biology, 1(12), 877–890. https://doi.org/10.1038/nsb1294-877
   PubMedGoogle Scholar
• Lee, H., Mok, K. H., Muhandiram, R., Park, K. H., Suk, J. E., Kim, D. H., Chang, J., Sung, Y. C., Choi, K. Y., & Han, K. H. (2000). Local structural elements in the mostly unstructured transcriptional activation domain of human p53. The Journal of Biological Chemistry, 275(38), 29426–29432. https://doi.org/10.1074/jbc.M003107200
   PubMed Web of Science ®Google Scholar
• Lee, H. J., Srinivasan, D., Coomber, D., Lane, D. P., & Verma, C. S. (2007). Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: A computational study. Cell Cycle (Georgetown, Tex.), 6(21), 2604–2611. https://doi.org/10.4161/cc.6.21.4923
   PubMed Web of Science ®Google Scholar
• Matlashewski, G., Lamb, P., Pim, D., Peacock, J., Crawford, L., & Benchimol, S. (1984). Isolation and characterization of a human p53 cDNA clone: Expression of the human p53 gene. The EMBO Journal, 3(13), 3257–3262. https://doi.org/10.1002/j.1460-2075.1984.tb02287.x
   PubMed Web of Science ®Google Scholar
• McBride, O. W., Merry, D., & Givol, D. (1986). The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proceedings of the National Academy of Sciences of the United States of America, 83(1), 130–134. https://doi.org/10.1073/pnas.83.1.130
   PubMed Web of Science ®Google Scholar
• Michino, M., & Brooks, C. L. (2009). Predicting structurally conserved contacts for homologous proteins using sequence conservation filters. Proteins, 77(2), 448–453. https://doi.org/10.1002/prot.22456
   PubMed Web of Science ®Google Scholar
• Nikolova, P. V., Wong, K. B., DeDecker, B., Henckel, J., & Fersht, A. R. (2000). Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. The EMBO Journal, 19(3), 370–378. https://doi.org/10.1093/emboj/19.3.370
   PubMed Web of Science ®Google Scholar
• Ozaki, T., & Nakagawara, A. (2011). Role of p53 in cell death and human cancers. Cancers, 3(1), 994–1013. https://doi.org/10.3390/cancers3010994
   PubMedGoogle Scholar
• Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kale, L., & Schulten, K. (2005). Scalable molecular dynamics with NAMD. Journal of Computational Chemistry, 26(16), 1781–1802. https://doi.org/10.1002/jcc.20289
   PubMed Web of Science ®Google Scholar
• Riley, T., Sontag, E., Chen, P., & Levine, A. (2008). Transcriptional control of human p53-regulated genes. Nature Reviews. Molecular Cell Biology, 9(5), 402–412. https://doi.org/10.1038/nrm2395
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham, T. E. (2013). PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. Journal of Chemical Theory and Computation, 9(7), 3084–3095. https://doi.org/10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Romer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J. (2006). p53-a natural cancer killer: Structural insights and therapeutic concepts. Angewandte Chemie (International ed. in English), 45(39), 6440–6460. https://doi.org/10.1002/anie.200600611
   PubMed Web of Science ®Google Scholar
• Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., & Appella, E. (2000). Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. The Journal of Biological Chemistry, 275(13), 9278–9283. https://doi.org/10.1074/jbc.275.13.9278
   PubMed Web of Science ®Google Scholar
• Sigler, P. B. (1988). Transcriptional activation. Acid blobs and negative noodles. Nature, 333(6170), 210–212. https://doi.org/10.1038/333210a0
   PubMed Web of Science ®Google Scholar
• Uesugi, M., & Verdine, G. L. (1999). The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. Proceedings of the National Academy of Sciences of the United States of America, 96(26), 14801–14806. https://doi.org/10.1073/pnas.96.26.14801
   PubMed Web of Science ®Google Scholar
• Uversky, V. N., Oldfield, C. J., & Dunker, A. K. (2008). Intrinsically disordered proteins in human diseases: Introducing the D2 concept. Annual Review of Biophysics, 37, 215–246. https://doi.org/10.1146/annurev.biophys.37.032807.125924
   PubMed Web of Science ®Google Scholar
• Wells, M., Tidow, H., Rutherford, T. J., Markwick, P., Jensen, M. R., Mylonas, E., Svergun, D. I., Blackledge, M., & Fersht, A. R. (2008). Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proceedings of the National Academy of Sciences of the United States of America, 105(15), 5762–5767. https://doi.org/10.1073/pnas.0801353105
   PubMed Web of Science ®Google Scholar
• Yee, K. S., & Vousden, K. H. (2005). Complicating the complexity of p53. Carcinogenesis, 26(8), 1317–1322. https://doi.org/10.1093/carcin/bgi122
   PubMed Web of Science ®Google Scholar
• Zilfou, J. T., & Lowe, S. W. (2009). Tumor suppressive functions of p53. Cold Spring Harbor Perspectives in Biology , 1(5), a001883–a001883. https://doi.org/10.1101/cshperspect.a001883
   PubMed Web of Science ®Google Scholar